anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although numerous studies have acknowledged disparities in epilepsy-related disease processes between young and aged animals, little is known about how epilepsy changes from young adulthood to middle age. This study investigates the impact of aging on 6-Hz corneal kindling in young-adult mice and middle-aged mice. We found that the kindling acquisition of the 6-Hz corneal kindling model was delayed in middle-aged mice when compared to young-adult mice. While the seizure stage and incidence of generalized seizures (GS) were similar between the two age groups, the duration of GS in the kindled middle-aged mice was shorter than that in the kindled young-adult mice. Besides, all kindled mice, regardless of age, were resistant to phenytoin sodium (PHT), valproate sodium (VPA), and lamotrigine (LGT), whereas middle-aged mice exhibited higher levetiracetam (LEV) resistance compared to young-adult mice. Both age groups of kindled mice displayed hyperactivity and impaired memory, which are common behavioral characteristics associated with epilepsy. Furthermore, middle-aged mice displayed more pronounced astrogliosis in the hippocampus. Additionally, the expression of Brain-Derived Neurotrophic Factor (BDNF) was lower in middle-aged mice than in young-adult mice prior to kindling. These data demonstrate that both the acquisition and expression of 6-Hz corneal kindling are attenuated in middle-aged mice, while hippocampal astrogliosis and pharmacological resistance are more pronounced in this age group. These results underscore the importance of considering age-related factors when utilizing the 6-Hz corneal kindling model in mice of varying age groups.
<P>PROBLEM TO BE SOLVED: To provide a composition containing hydrogen peroxide that prevents lowered stability of hydrogen peroxide and gives the hair a favorable touch.  <P>SOLUTION: The composition containing hydrogen peroxide includes (A) hydrogen peroxide, at least (B) one kind selected from guar gum and its derivatives (C) a cationized polymer obtained from a polymer other than cationized guar gum and its derivatives, (D) water, and other components. Preferably the composition contains at least (E) one kind selected from 1- hydroxyethane-1, 1-diphosphonic acid, and its salts. Preferably the composition contains (F) an amphoteric polymer. Preferably component (B) is cationized guar gum. The composition is used for a hair dye, a hair bleach, a dye bleach, etc.  <P>COPYRIGHT: (C)2004,JPO
Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he "limited" CCRT arm comparable exposure to the cognitive games training as with the "full CCRT" arm, with the exception of the titrating nature of the game training.
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.

Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
PROBLEM TO BE SOLVED: To obtain a capsule having good disintegrating properties. SOLUTION: This capsule comprises vitamin E, vitamin C, a processed garlic and a surfactant having >11 hydrophile-lypophile balance(HLB) value. A sucrose glycerol fatty acid ester is preferred as the surfactant. Amounts of the ingredients formulated based on 1 pt.wt. of the vitamin E are 0.1-3 pts.wt. of the vitamin C, 0.1-1 pt.wt. of the processed garlic and 0.02-0.5 pt.wt. of the surfactant.
NEW MATERIAL:The GOO69C substance of formula and its salt. It has the following physical and chemical properties. Appearance, pale brown powder; molecular weight, 287 (by fast atomic-bombardment mass-spectrometry); solubility, easily soluble in water and hardly soluble in ether and chloroform; etc. USE:Carcinostatic agent and antibacterial agent. PREPARATION:The titled substance can be produced e.g. by culturing Streptomyces brunneogriseus Furumai et Okuda subsp. bannaensis GOO69 strain (FERM-BP 706) capable of producing GOO69C substance usually in a liquid medium under aeration and agitation preferably at 25-40 deg.C usually for 30-100hr.
One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
Hydrocortisone Valerate Cream USP, 0.2% contains hydrocortisone valerate, 11,21-dihydroxy-17-[(1-oxopentyl)oxy]-(11β)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.

Chemically, hydrocortisone valerate is C26H38O6. It has the following structural formula:

Hydrocortisone valerate has a molecular weight of 446.58. It is a white, crystalline solid, soluble in ethanol and methanol, sparingly soluble in propylene glycol and insoluble in water.

Each gram of Hydrocortisone Valerate Cream USP, 0.2% contains 2mg hydrocortisone valerate in a hydrophilic base composed of amphoteric-9, carbomer homopolymer type C, dibasic sodium phosphate, propylene glycol, purified water, sodium lauryl sulfate, sorbic acid, stearyl alcohol, and white petrolatum.
Systemic glucocorticoids are the mainstay of treatment for active moderate-to-severe Graves' orbitopathy. However, there are a number of different glucocorticoid regimens with different total dosage, schemes of administration and duration. The goal of this interventional study is to compare the effectiveness of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves' orbitopathy. The main questions it aims to answer are:

1. Are the two glucocorticoid regimens similarly effective?
2. Do the two glucocorticoid regimens have similar safety profile? The patients involved are treated with one of the two glucocorticoid regimens. The first group is treated with modified monthly regimen, including 3 pulses of 3 infusions of 500 mg methylprednisolone administered in three consecutive months, with application of 125 mg methylprednisolone intramuscularly once per week between the pulses. Total cumulative dose - 5.5. g., duration - 3 months. After completion of the venous infusions, a low dose peroral glucocorticoid therapy is prescribed for the next 3 months. The second group is treated with weekly glucocorticoid regimen: 6 infusions of 500 mg methylprednisolone during the first 6 weeks followed by 6 infusions of 250 mg methylprednisolone during the next 6 weeks. Total cumulative dose - 4.5 g., duration - 3 months. Patients' ocular status and therapeutic response are assessed at 1st, 3rd and 6th months; quality of life - at 3rd and 6th month.
Spinal stiffness plays an important role in the assessment of the spine in the clinical daily routine. It is often performed as a manual PA-pressure test in the prone position. The spinal stiffness is the result of the resistance from the active, passive and neurological subsystems, like muscles (active), ligaments, joint capsule and the skin (passive). Further research had shown, that the spinal stiffness depends also from other factors. It is increased by axial compression. A better understanding of spinal stiffness leads to novel insights into spinal stabilization mechanisms.
FIELD: medicine, allergology. SUBSTANCE: method involves correction of intestine dysbacteriosis using diet, adsorbents, coating agents, enzyme and bacterial preparations and eubiotics. Treatment with eubiotics and bacterial preparations is carried out by the following schedule: intetrix is given to patient in a dose 1 capsule, 4 times per a day after eating for 5-7 days and after termination of this course bactisubtil is given in a dose 2 capsules, 3 times per a day between food intake for 2 weeks. After termination of this course bificol is given to patient, by 5 doses, 3 times per a day, 40 min before eating and chilack is given in dinner in a dose by 40 drops before eating for 4 weeks. After termination of this course control analysis for dysbacteriosis is carried out. Eubiosis fact is interpreted as positive dynamics and treatment is terminated. In the case of alienated repeated symptoms of allergy treatment course is repeated. Method recoveries the normal microflora of large intestine. EFFECT: decreased frequency of disease relapses, decreased period of treatment. 2 tbl, 2 ex
Emicizumab is a bispecific antibody that mimics the function of factor VIII (FVIII) and is indicated for prophylactic use in patients with congenital hemophilia A with or without inhibitors. Acquired hemophilia A (AHA) is a rare and severe disorder causes by autoantibodies that inhibit FVIII. In AHA, acute bleeding are managed with bypassing agents but several reports described the off-label use of emicizumab. The aim of this article is to describe two cases of AHA treated with emicizumab and a review of the scientific littérature. Reports indicate that the use of emicizumab is efficacious to treat acute bleeding with less thrombotic events thant with bypassing agents and with a reduced hospitalisation duration. Nevertheless biological monitoring is more complicated with assay interferences and a persistent circulation more than 6 months after the last injection was observed for our two patients.
NEW MATERIAL:An anti-TPA monoclonal antibody bonding to tissue plasminogen activator(TPA) competitively with plasminogen activator inhibitor(PAI) and not neutralizing the enzymatic activity of the TPA. USE:The bonding of the antibody to TPA for preventing the inactivation of the TPA with PAI gives an effective fibrinolytic agent slightly having adverse reactions. The agent can be utilized for an immunological measurement method for highly sensitively and specifically measuring TPA. PREPARATION:Antibody-producing cells such as splenic cells are first collected from an animal immunized with TPA and fused with myeloma cells. The objective antibody-producing cells are screened from the prepared hydridoma and cloned. The cloned cells are multiplied to produce the antibody.
The invention discloses Tricyrtis macropoda Miq. root or herb-flavored bastardtoadflaxlike swallowwort herb and fruit jam and a making method thereof. By using Tricyrtis macropoda Miq. root or herb and bastardtoadflaxlike swallowwort herb and fruit as raw materials and simultaneously adding the seed of Job's tears and fiveleaf akebia root, the Tricyrtis macropoda Miq. root or herb-flavored bastardtoadflaxlike swallowwort herb and fruit jam is prepared. By fully using nutritional value of Tricyrtis macropoda Miq. root or herb and bastardtoadflaxlike swallowwort herb and fruit and through synergism of Chinese herbal medicines, the product has effects of clearing heat and decreasing internal heat and helping produce saliva and slake thirst. By primary fermentation of Cucumis metuliferus with the use of distiller's yeast of fruit wine, mellow fragrance of the product is increased. By primary fermentation of Chinese herbal medicines with the use of liqueur koji, bitter taste of the Chinese herbal medicines is effectively removed. The prepared product has fresh and sweet taste, is mellow and tasty, has unique flavor, has prominent health-care function, and can obviously improve discomfort of people with body fluid deficiency and thirst if being eaten for a long time. The preparation technology is simple, conforms to the development of the times, and can be applied for large-scale production.
Appendicitis is one of the most common abdominal emergencies. Evidence is controversial in determining if the in-hospital time delay to surgery can worsen the clinical presentation of appendicitis. This study aimed to clarify if in-hospital surgical delay significantly affected the proportion of complicated appendicitis in a large prospective cohort of patients treated with appendectomy for acute appendicitis. Patients were grouped into low, medium, and high preoperative risk for acute appendicitis based on the Alvarado scoring system. Appendicitis was defined as complicated in cases of perforation, abscess, or diffuse peritonitis. The primary outcome was correlation of in-hospital delay with the proportion of complicated appendicitis. The study includes 804 patients: 278 (30.4%) had complicated appendicitis and median time delay to surgery in low-, medium-, and high-risk group was 23.15 h (13.51-31.48), 18.47 h (10.44-29.42), and 13.04 (8.13-24.10) h, respectively. In-hospital delay was not associated with the severity of appendicitis or with the presence of postoperative complications. It appears reasonably safe to delay appendicectomy for acute appendicitis up to 24 h from hospital admission. Duration of symptoms was a predictor of complicated appendicitis and morbidity. Timing for appendicectomy in acute appendicitis should be calculated from symptoms onset rather than hospital presentation.
<P>PROBLEM TO BE SOLVED: To provide a novel composite suture and suture anchor combination by which suitable tensile strength with minimum amount of high tensile strength material can be obtained, excellent knot strength and knot safety can be achieved, and the profile of a knot in an organism is contracted as time passes to enable implantation of tissue.  <P>SOLUTION: A novel high tensile strength semi-absorbable composite suture with minimized non-absorbable mass. The suture has a core made from a bioabsorbable polymer. The core is covered by a braided sheath. The braided sheath is made from an absorbable yarn and a bioabsorbable yarn. The bioabsorbable yarn is made from at least one filament of a bioabsorbable polymer. The nonabsorbable yarn is formed of at least one filament of ultra high molecular weight polyethylene.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
<P>PROBLEM TO BE SOLVED: To provide a highly effective anti-inflammatory/analgesic composition for external application by increasing skin permeability of a nonsteroidal anti-inflammatory/analgesic agent.  <P>SOLUTION: The anti-inflammatory/analgesic composition for external application contains the nonsteroidal anti-inflammatory/analgesic agent and a starch powder. The nonsteroidal anti-inflammatory/analgesic agent is used for chronic rheumatism, osteoarthritis and acute and chronic musculoskeletal pains but generally has a side effect such as gastrointestinal injury. Therefore, various formulations other than oral agents such as external preparations and suppositories have been developed and used for medical practice. The present invention solves the problem associated with the external preparations wherein satisfactory effects could not be achieved due to a marked deterioration in the skin permeability of the drug induced by a biological barrier effect of keratin.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To obtain a preparation preventing staining of e.g. the oral cavity, tongue and easy to be administered by including a salt of copper chlorophylline and acid(s). SOLUTION: This preparation contains (A) a salt of copper chlorophylline, preferably potassium copper chlorophylline or sodium copper chlorophylline and (B) 0.1-10 pt(s).wt., per pt.wt. of the ingredient A, of acid(s), preferably, at least one acid selected from ascorbic acid, tartaric acid, citric acid, malic acid and the like. Furthermore, medicinal ingredient(s), e.g. antidiarrheal drug(s), drug(s) for controlling intestinal function, antiulcer drug(s) may be compounded in this preparation. It is preferable this preparation is used in the form of solid, particularly, e.g. chewable form, troche form.
PURPOSE:A hair nourishing material, consisting of the first tablet containing well-balanced specific 6 kinds of vitamins and the second tablet containing adequate amounts of a hypotensive agent and tranquilizer and a specific amount or more of seaweed, etc. having preventing action on aging phenomenon and blackening action on hair, and taken at each meal. CONSTITUTION:A hair nourishing material constituted of the first tablet containing well-balanced VA, VB, VB2, VB6, VC and VE in vitamins, the second tablet containing a hypotensive agent and tranquilizer in adequate amounts and >=50g side dish, e.g. seaweed and/or yellow green vegetable treated in the state close to the natural one and vacuum packed. The aging phenomenon, e.g. turning gray of hair, depilation, etc., can be prevented and further blackening action on hair is produced by taking the above-mentioned material at each meal. Preferably, the first tablet contains 2,000VA units vitamin A oil, 5.0mg each thiamine hydrochloride, pyridoxine hydrochloride and alpha-tocopherol, 2.0mg riboflavin and 50.0mg sodium alpha-ascorbate in one tablet.
The invention provides a novel wart eliminating tincture which has a good wart eliminating effect, does not have toxic or side effect and is convenient to use, and a preparation method thereof. The novel wart eliminating tincture is prepared from the following raw materials in percentage by weight: 15-20% of each of pinellia, khosams, purslane and isatis root, and 8-2% of each of dyers woad leaf and coix seeds. The preparation method comprises the following steps: removing shells of the khosams, crushing the khosams and the other medicines into powder respectively, uniformly mixing, pouring the mixture into 75% alcohol for soaking for 1 week, wherein the medicines account for 30-1% and the alcohol accounts for 60-70%. The using method of the novel wart eliminating tincture comprises the following steps: dipping the liquid medicine and applying the liquid medicine to affected parts for 2-3 times every day. For normal wart points, the curative effect is better when the tincture is applied to the affected parts after the normal wart points are stabbed to bleed. In the novel wart eliminating tincture provided by the invention, the purslane, isatis root and dyers woad leaf can clear heat and toxic materials, the coix seeds can be used for clearing heat and promoting diuresis, the khosams can be used for removing dampness and destroying parasites, and the pinellia can be used for removing dampness and removing stasis. The six medicines work together to kill all wart cells and eliminate wart viruses. The novel wart eliminating tincture has an extremely good wart eliminating effect.
FIELD: biological engineering. SUBSTANCE: polypeptides possessing properties of hepatitis C virus internal antigen are obtained. The polypeptides are capable of binding antibodies to hepatitis C virus Cor-antigen. After having been administered to experimental animals, the polypeptides invoke formation of specific antibodies to hepatitis C virus Cor-antigen. The polypeptides are synthesized by Escherichia coli bacterial strain produced by transforming PLT90 strain with pH 365 F recombinant plasmids possessing nucleotide sequence of Escherichia coli Cor-antigen gen. EFFECT: enhanced effectiveness in detecting hepatitis C virus antibodies and producing specific antibodies. 3 cl
We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
This invention relates to the extraction of psychoactive compounds from fungus for use in medicine. Raw fungus is dried and ground. The solvent used for extraction is methanol or a hydro-methanol mixture, an acidic hydro-methanol mixture, or an alkaline hydro-methanol mixture. The extraction slurry is filtered and pH-adjusted if necessary. The methanol in the solvent is then completely evaporated and water added back, where necessary, to form a concentrated slurry. The concentrated slurry is then standardized to provide a known concentration of the psychoactive alkaloids that have been extracted.  The standardized slurry may then be dried to result in a powdered extract with a precisely defined purity of psychoactive compounds.
Aspects include incorporating media communication adaptors in a surgical environment. Wireless communication can be established between one or more data adaptors and a central processing hub in a surgical system. The one or more data adaptors can be configured to provide surgical data associated with a surgical procedure. Localized processing of the surgical data can be performed at the one or more data adaptors prior to sending the surgical data to the central processing hub. Localized processing of video associated with the surgical data can be performed at one or more video adaptors prior to sending processed video or an output of the video to the central processing hub. The surgical data and the video can be further processed at the central processing hub.